Evidence map›Paper›PMID 39763616›Full record

ArticleJournal of pharmaceutical policy and practice2024

'We need to be part of the solution': lessons from the 2024 PPRI Conference on ensuring access to affordable medicines through innovative policies.

Sabine Vogler, Nina Zimmermann, Verena Knoll, Maximilian Salcher-Konrad, Friederike Windisch, Jaime Espin, Aukje K Mantel-Teeuwisse, Dimitra Panteli, Fatima Suleman, Veronika J Wirtz and 1 more

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sabine VoglerWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute), Vienna, Austria.ORCID https://orcid.org/0000-0003-4853-4397
Nina ZimmermannQuality Management and Certification Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute), Vienna, Austria.
Verena KnollWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute), Vienna, Austria.ORCID https://orcid.org/0009-0001-2685-689X
Maximilian Salcher-KonradWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute), Vienna, Austria.ORCID https://orcid.org/0000-0002-5628-5266
Friederike WindischWHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (Austrian National Public Health Institute), Vienna, Austria.ORCID https://orcid.org/0000-0001-8364-9646
Jaime EspinAndalusian School of Public Health, Granada, Spain.ORCID https://orcid.org/0000-0001-7299-6554
Aukje K Mantel-TeeuwisseWHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht University, Utrecht, the Netherlands.ORCID https://orcid.org/0000-0002-8782-0698
Dimitra PanteliEuropean Observatory on Health Systems and Policies, Brussels, Belgium.ORCID https://orcid.org/0000-0003-2110-3335
Fatima SulemanWHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.ORCID https://orcid.org/0000-0002-8559-9168
Veronika J WirtzWHO Collaborating Center in Pharmaceutical Policy, Department of Global Health, Boston University School of Public Health, Boston, USA.ORCID https://orcid.org/0000-0002-0863-8768
Zaheer-Ud-Din BabarCollege of Pharmacy, Qatar University, Doha, Qatar.ORCID https://orcid.org/0000-0003-3664-8901

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On 25-26 April 2024, the 5th PPRI (Pharmaceutical Pricing and Reimbursement Information) Conference on ensuring equitable access to affordable medicines took place in Vienna (Austria). Twenty-four accepted contributions were presented either as oral presentations or posters, adding to invited keynote lectures, stakeholder debates and workshops. The global multi-stakeholder audience discussed a range of approaches in pharmaceutical policies, which have the potential to successfully and sustainably address current and future challenges in ensuring patient access to affordable medicines globally. These discussions benefited from the interaction between policy-makers, stakeholders in the private sector and researchers who provided evidence on implemented and piloted policies. Among the policy options that drew the most attention during the PPRI Conference were procurement with targeted instruments to achieve strategic objectives, innovative payment models such as different variants of managed-entry agreements, and new models to fund pharmaceutical research and development. Experiences on established policy options that are being newly introduced in several countries, such as price regulation, health technology assessment, evidence-based selection for reimbursement decisions and measures to enhance the uptake of biosimilar medicines were also shared. The PPRI Conference reaffirmed the relevance of pharmaceutical pricing, procurement and reimbursement policies aligned with policy actions in other areas and along the pharmaceutical life-cycle and emphasised the importance of developing needs-driven health systems. Innovation in policy-making is needed to work towards equitable patient access to affordable medicines. This requires transparency, alignment on evidence requirements, communication, coordination, intra-country and international collaboration, solidarity and trust.

Indexed as

Access to medicinescollaborationevidencepricesolidaritytransparency

Identifiers

PMID39763616
PMCPMC11703438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.